作者
Ciro Celsa, Giuseppe Cabibbo, Claudia AM Fulgenzi, Bernhard Scheiner, Antonio D’Alessio, Giulia F Manfredi, Naoshi Nishida, Celina Ang, Thomas U Marron, Anwaar Saeed, Brooke Wietharn, Matthias Pinter, Jaekyung Cheon, Yi-Hsiang Huang, Pei-Chang Lee, Samuel Phen, Anuhya Gampa, Anjana Pillai, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Natascha Roehlen, Robert Thimme, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G Singal, Paul El Tomb, Susanna Ulahannan, Alessandro Parisi, Hong Jae Chon, Wei-Fan Hsu, Bernardo Stefanini, Elena Verzoni, Raffaele Giusti, Antonello Veccia, Annamaria Catino, Giuseppe Aprile, Pamela Francesca Guglielmini, Marilena Di Napoli, Paola Ermacora, Lorenzo Antonuzzo, Ernesto Rossi, Francesco Verderame, Fable Zustovich, Corrado Ficorella, Francesca Romana Di Pietro, Nicola Battelli, Giorgia Negrini, Francesco Grossi, Roberto Bordonaro, Stefania Pipitone, Maria Banzi, Serena Ricciardi, Letizia Laera, Antonio Russo, Ugo De Giorgi, Luigi Cavanna, Mariella Sorarù, Vincenzo Montesarchio, Paola Bordi, Leonardo Brunetti, Carmine Pinto, Melissa Bersanelli, Calogero Cammà, Alessio Cortellini, David J Pinato
发表日期
2024/3/1
期刊
Journal of hepatology
卷号
80
期号
3
页码范围
431-442
出版商
Elsevier
简介
Background & Aims
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours.
Methods
Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line atezolizumab+bevacizumab from the AB-real study, and a non-HCC cohort including 459 patients treated with first-line ICI therapy from the INVIDIa-2 multicentre study. IrLI was defined as a treatment-related increase of aminotransferase levels after exclusion of alternative aetiologies of liver injury. The incidence of irLI was adjusted for the duration of treatment exposure.
Results
In patients with HCC, the incidence of any grade irLI was 11.4% over a median treatment …
学术搜索中的文章
C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner… - Journal of hepatology, 2024
